Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
暂无分享,去创建一个
M. Grever | R. Kloos | M. Villalona-Calero | M. Ringel | M. Shah | J. Zwiebel | J. Woyach | M. Collamore | D. Arbogast | Minden Collamore | M. Shah
[1] B. Thiers. Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma , 2008 .
[2] V. Papadimitrakopoulou,et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer , 2008, Investigational New Drugs.
[3] N. Fortunati,et al. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. , 2007, Endocrine-related cancer.
[4] Chunlei Zhang,et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.
[5] O. Bosco,et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. , 2006, The Journal of endocrinology.
[6] G. Braunstein,et al. Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo , 2006, Clinical Cancer Research.
[7] Mithat Gonen,et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.
[8] E. Mazzaferri. The Prognostic Value of Primary Tumor Size in Papillary and Follicular Thyroid Carcinoma: A Comparative AnalysisMachens A, Holzhausen H-J, Dralle H (Martin-Luther-Univ Halle-Wittenberg, Halle/Saale, Germany) Cancer 103:2269–2273, 2005§ , 2006 .
[9] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[10] L. Schwartz,et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Marks,et al. Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer , 2005, Clinical Cancer Research.
[12] J. Arts,et al. Histone Deacetylase Inhibitors: From Chromatin Remodelling to Experimental Cancer Therapeutics , 2005 .
[13] T. Endo,et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. , 2004, Endocrinology.
[14] G. Otterson,et al. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. , 2003, Current medicinal chemistry. Anti-cancer agents.
[15] D. Conrad,et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. , 2003, Cancer research.
[16] Q. Duh,et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. , 2002, Surgery.
[17] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[18] M. Grever,et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] W. Wilson,et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.
[20] L. Grochow,et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] T. Fojo,et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. , 2001, The Journal of clinical endocrinology and metabolism.
[22] D. Lee,et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. , 2001, European journal of nuclear medicine.
[23] S. Larson,et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[24] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[25] M. Schlumberger,et al. Papillary and follicular thyroid carcinoma. , 1998, The New England journal of medicine.
[26] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[27] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[28] M. Schlumberger. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. , 1999, Journal of endocrinological investigation.
[29] I. Fleming,et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.
[30] J. Workman,et al. Alteration of nucleosome structure as a mechanism of transcriptional regulation. , 1998, Annual review of biochemistry.
[31] J. Shah,et al. Differentiated thyroid cancer presenting initially with distant metastasis. , 1997, American journal of surgery.
[32] M. Schlumberger,et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.